Jonathan Benjamin

Clinical Trials

• Recruiting Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)
• Recruiting Post T-plant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidate Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
• Recruiting Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
• Recruiting Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
• Recruiting Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
• Recruiting Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
• Recruiting Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
• Not Recruiting Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
• Not Recruiting Comparing Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation in Individuals With Hematologic Cancers
• Not Recruiting Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
• Not Recruiting Ph II of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
• Not Recruiting A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
• Not Recruiting A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
• Recruiting Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
• Recruiting Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)